CD34+ hematopoietic progenitor cell dose as a predictor of engraftment and survival in multiple myeloma patients undergoing autologous stem cell transplantation | Zendy

Elifcan Aladağ | Zendy; Halûk Demiroğlu | Zendy; Yahya Büyükaşık | Zendy; Mehmet Turgut | Zendy; Salih Aksu | Zendy; Nilgün Sayınalp | Zendy; İbrahim C. Haznedaroğlu | Zendy; Osman Özcebe | Zendy; Hakan Göker | Zendy

Open Access

CD34+ hematopoietic progenitor cell dose as a predictor of engraftment and survival in multiple myeloma patients undergoing autologous stem cell transplantation

Author(s) -

Elifcan Aladağ,

Halûk Demiroğlu,

Yahya Büyükaşık,

Mehmet Turgut,

Salih Aksu,

Nilgün Sayınalp,

İbrahim C. Haznedaroğlu,

Osman Özcebe,

Hakan Göker

Publication year - 2020

Publication title -

turkish journal of medical sciences

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.277

H-Index - 27

eISSN - 1303-6165

pISSN - 1300-0144

DOI - 10.3906/sag-2001-173

Subject(s) - medicine , cd34 , melphalan , multiple myeloma , hematopoietic stem cell transplantation , transplantation , progenitor cell , autologous stem cell transplantation , stem cell , haematopoiesis , leukapheresis , absolute neutrophil count , surgery , urology , gastroenterology , chemotherapy , neutropenia , genetics , biology

High-dose melphalan and autologous hematopoietic stem cell transplantation (AHSCT) is the standard treatment strategy for multiple myeloma (MM) patients who are eligible for it. The recommended dose of CD34+ hematopoietic progenitor cells (HPCs) for adequate engraftment is above 2 × 106/kg. The aim of this study was to evaluate the relationship between the dose of CD34+HPCs and survival in MM patients who underwent AHSCT at a tertiary care center.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research